Hostname: page-component-76fb5796d-r6qrq Total loading time: 0 Render date: 2024-04-25T08:04:33.316Z Has data issue: false hasContentIssue false
  • English
  • Français

The nasal distribution of metered does inhalers

Published online by Cambridge University Press:  29 June 2007

S. P. Newman ,
F. Morén  and
S. W. Clarke
S. P. Newman*
Affiliation:
Department of Thoracic Medicine, Royal Free Hospital, Pond Street, London NW3 2QG, England.
F. Morén
Affiliation:
AB Draco (Subsidiary to AB Astra), Research and Developenent Laboratorics, Box 34, S-221 00 Lund, Sweden. (Current address: Sjukhusapeteket, Lasarettet, S-25187, Helsingborg, Sweden.)
S. W. Clarke
Affiliation:
Department of Thoracic Medicine, Royal Free Hospital, Pond Street, London NW3 2QG, England.
*
Dr. S. P. Newman, Ph.D., Department of Thoracic Medicine, Royal Free Hospital, Pond Street, London, NE3 2QG.
Get access Rights & Permissions [Opens in a new window]

Abstract

The intranasal distribution of aerosol from a metered dose inhaler has been assessed using a radiotracer technique. Inhalers were prepared by adding 99Tcm-labelled Teflon particles (simulating the drug particles) to chlorofluorocarbon propellants, and scans of the head (and chest) taken with a gamma camera. Ten healthy subjects (age range 19–29 years) each performed two radioaerosol studies with the inhaler held in two different ways: either in a single position (vial pointing upwards) or in two positions (vial pointing upwards and then tilted by 30° in the sagittal plane).

The vast majority of the dose (82.5 ± 2.8 (mean ± SEM) per cent and 80.7 ± 3.1 per cent respectively for one-position and two-position studies) was deposited on a single localized area in the anterior one-third of the nose, the initial distribution pattern being identical for each study. No significant radioaerosol was detected in the lungs. Only 18.0 ± 4.7 per cent and 15.4 ± 4.1 per cent of the dose had been removed by mucociliary action after 30 minutes, and it is probable that the remainder had not penetrated initially beyond the vestibule. Since the deposition pattern was highly localized and more than half the dose probably failed to reach the turbinates it is possible that the overall effect of nasal MDIs is suboptimal for the treatment of generalized nasal disorders.

Type
Research Article
Information
The Journal of Laryngology & Otology , Volume 101 , Issue 2 , February 1987 , pp. 127 - 132
Copyright
Copyright © JLO (1984) Limited 1987

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Balle, V. H. (1982) The effect of budesonide in perennial rhinitis. European Journal of Respiratory Diseases, 63 (Supplement 122): 197–204.Google Scholar
Borum, P., Molgaard, F. and Mygind, N. (1983) Studies with intranasal ipratropium in rhinitis. European Journal of Respiratory Diseases, 64 (Supplement 126): 125–128.Google Scholar
British Pharmaceutical Codex (1977) Aerosol inhalations, Pharmaceutical Press, London, pp. 643–648.Google Scholar
Cockcroft, D. W., MacCormack, D. W., Newhouse, M. T. and Hargreave, F. E. (1976) Beclomethasone dipropionate aerosol in allergic rhinitis. Canadian Medical Association Journal, 115: 523–526.Google ScholarPubMed
Dirksen, H., Groth, S. and Mygind, N. (1983) The bronchodilating effect of fenoterol after intranasal administration. European Journal of Respiratory Diseases, 64 (Supplement 128): 116–118.Google Scholar
Holopainen, E., Grahne, B., Malmberg, H., Makinen, J. and Lindqvist, N. (1982) Budesonide in the treatment of nasal polyposis. European Journal of Respiratory Diseases, 63 (Supplement 122): 221–228.Google Scholar
Kim, C. S., Eldridge, M. A., Sackner, M. A. and Swift, D. L. (1985) Deposition of aerosol particles in the human nose. American Review of Respiratory Disease, 131: A370.Google Scholar
Morén, F. (1981) Pressurized aerosols for oral inhalation. International Journal of Pharmaceutics, 8: 1–10.CrossRefGoogle Scholar
Mygind, N. (1982) Intranasal corticosteroid treatment of rhinitis. European Journal of Respiratory Diseases, 63 (Supplement 122): 192–196.Google Scholar
Mygind, N. (1985) In Aerosols in Medicine (Morén, F., Newhouse, M. T. and Dolovich, M. B., eds.), pp. 1–20, Elsevier Biomedical Press, Amsterdam.Google Scholar
Mygind, N. and Vesterhauge, S. (1978) Aerosol distribution in the nose. Rhinology, 16: 79–88.Google ScholarPubMed
Newman, S. P. and Clarke, S. W. (1983) Therapeutic aerosols I: Physical and practical aspects. Thorax, 38: 881–886.CrossRefGoogle Scholar
Newman, S. P., Pavia, D., Moren, F., Sheahan, N. F. and Clarke, S. W. (1981) Deposition of pressurized aerosols in the human respiratory tract. Thorax, 36: 52–55.CrossRefGoogle ScholarPubMed
Newman, S. P., Millar, A. B., Lennard-Jones, T. R., Morén, F. and Clarke, S. W. (1984) Improvement of pressurized aerosol deposition in the human lung with Nebuhaler spacer device. Thorax, 39: 935–941.CrossRefGoogle ScholarPubMed
Philipson, K. (1973) On the production of mono-disperse particles with a spinning disc. Journal of Aerosol Science, 4: 51–57.CrossRefGoogle Scholar
Pipkorn, U. and Berge, T. (1983) Long-term treatment with budesonide in vasomotor rhinitis. Acta Otolaryngologica, 95: 167–171.Google Scholar
Proctor, D. F. (1982) In The Nose (Proctor, D. F. and Andersen, I., eds.), pp. 23–43, Elsevier Biomedical Press, Amsterdam.Google Scholar
Proctor, D. F. (1985) In Transnasal Systemic Medications (Chien, Y. W., ed.), pp. 101–106, Elsevier Biomedical Press, Amsterdam.Google Scholar
Von Haacke, N. P., Moore-Gillon, V. and Capel, L. H. (1983a) A study of atrovent nasal in chronic rhinorrhoea. European Journal of Respiratory Diseases, 64 (Supplement 126): 129–131.Google Scholar
Von Haacke, N. P., Moore-Gillon, V. and Capel, L. H. (1983b) Double-blind cross-over trial of ipratropium and placebo in chronic watery rhinorrhoea. British Medical Journal, 287: 1258–1259.CrossRefGoogle Scholar